{"result": "(\"entity\"<|>KASPER DL<|>PERSON<|>Kasper DL is one of the editors of Harrison's Principles of Internal Medicine, contributing to the field of internal medicine.)\n##\n(\"entity\"<|>HAUSER SL<|>PERSON<|>Hauser SL is one of the editors of Harrison's Principles of Internal Medicine, known for his work in internal medicine.)\n##\n(\"entity\"<|>JAMESON JL<|>PERSON<|>Jameson JL is one of the editors of Harrison's Principles of Internal Medicine, recognized for his contributions to medical literature.)\n##\n(\"entity\"<|>FAUCI AS<|>PERSON<|>Fauci AS is one of the editors of Harrison's Principles of Internal Medicine, a prominent figure in infectious diseases.)\n##\n(\"entity\"<|>LONGO DL<|>PERSON<|>Longo DL is one of the editors of Harrison's Principles of Internal Medicine, contributing to various medical fields.)\n##\n(\"entity\"<|>LOSCANO J<|>PERSON<|>Loscano J is one of the editors of Harrison's Principles of Internal Medicine, involved in medical education and literature.)\n##\n(\"entity\"<|>FASSNACHT M<|>PERSON<|>Fassnacht M is a contributor to the European Society of Endocrinology Clinical Practice Guidelines on adrenal incidentalomas.)\n##\n(\"entity\"<|>ARLT W<|>PERSON<|>Arlt W is a contributor to the European Society of Endocrinology Clinical Practice Guidelines on adrenal incidentalomas.)\n##\n(\"entity\"<|>BANCOS I<|>PERSON<|>Bancos I is a contributor to the European Society of Endocrinology Clinical Practice Guidelines on adrenal incidentalomas.)\n##\n(\"entity\"<|>DRALLE H<|>PERSON<|>Dralle H is a contributor to the European Society of Endocrinology Clinical Practice Guidelines on adrenal incidentalomas.)\n##\n(\"entity\"<|>NEWELL-PRICE J<|>PERSON<|>Newell-Price J is a contributor to the European Society of Endocrinology Clinical Practice Guidelines on adrenal incidentalomas.)\n##\n(\"entity\"<|>SAHDEV A<|>PERSON<|>Sahdev A is a contributor to the European Society of Endocrinology Clinical Practice Guidelines on adrenal incidentalomas.)\n##\n(\"relationship\"<|>KASPER DL<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Kasper DL is an editor of Harrison's Principles of Internal Medicine, contributing to its content<|>7)\n##\n(\"relationship\"<|>HAUSER SL<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Hauser SL is an editor of Harrison's Principles of Internal Medicine, contributing to its content<|>7)\n##\n(\"relationship\"<|>JAMESON JL<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Jameson JL is an editor of Harrison's Principles of Internal Medicine, contributing to its content<|>7)\n##\n(\"relationship\"<|>FAUCI AS<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Fauci AS is an editor of Harrison's Principles of Internal Medicine, contributing to its content<|>7)\n##\n(\"relationship\"<|>LONGO DL<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Longo DL is an editor of Harrison's Principles of Internal Medicine, contributing to its content<|>7)\n##\n(\"relationship\"<|>LOSCANO J<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>Loscano J is an editor of Harrison's Principles of Internal Medicine, contributing to its content<|>7)\n##\n(\"relationship\"<|>FASSNACHT M<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Fassnacht M is a contributor to the European Society of Endocrinology Clinical Practice Guidelines<|>6)\n##\n(\"relationship\"<|>ARLT W<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Arlt W is a contributor to the European Society of Endocrinology Clinical Practice Guidelines<|>6)\n##\n(\"relationship\"<|>BANCOS I<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Bancos I is a contributor to the European Society of Endocrinology Clinical Practice Guidelines<|>6)\n##\n(\"relationship\"<|>DRALLE H<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Dralle H is a contributor to the European Society of Endocrinology Clinical Practice Guidelines<|>6)\n##\n(\"relationship\"<|>NEWELL-PRICE J<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Newell-Price J is a contributor to the European Society of Endocrinology Clinical Practice Guidelines<|>6)\n##\n(\"relationship\"<|>SAHDEV A<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>Sahdev A is a contributor to the European Society of Endocrinology Clinical Practice Guidelines<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , MA: UpToDate Inc. https://www.uptodate.com.                • Arlt W. Trastornos de la corteza suprarrenal. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison\n           Literature review current through: Apr. 2019.                                                                                       Principios de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2309-29.\n                                                                                                                                             • Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentaloma: European Society\n                                                                                                                                               of Endocrinology Clinical Practice. Guideline in collaboration with the European Network for the Study of adrenal tumors.\n                                                                                                                                               Eur J Endocrinol. 2016;175:G1-G34.\n     39  De entre las siguientes afirmaciones en relación con los incidentalomas                                                             • Recasens Sala M. Incidentaloma adrenal. Manual de Endocrinología y Nutrición. Disponible en: https://manual.seen.es\n         suprarrenales, señale la opción                  falsa:                                                                               (última modificación: 25 de noviembre de 2015).\n                                                                                                                                             • Steward PM, Newell-Price JDC. The adrenal cortex. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n                                                                                                                                               of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 490-555.\n         A. La secreción autónoma de cortisol no es un buen predictor del desarrollo de un síndrome                                          • Young WF, Jr, Kebebew E. The adrenal incidentaloma. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com.\n             de Cushing.                                                                                                                       Literature review current through: Apr. 2019.\n         B. La determinación periódica sistemática de análisis de función suprarrenal no es\n             necesaria después de una evaluación inicial normal.\n         C. La 17-hidroxiprogesterona debería ser medida en caso de incidentaloma suprarrenal\n             bilateral.\n         D.  La suprarrenalectomía laparoscópica es el tratamiento indicado en la mayoría de los\n             incidentalomas.\n\n\n\n         COMENTARIO\n         El estudio de funcionalidad de un incidentaloma suprarrenal tiene como objetivo final poder\n         decidir qué pacientes deberían ser sometidos a la exéresis de la lesión.\n\n\n\n294                                                                                                                                                                                                                                                                              295\n---\n                                                                                                                                                                                                                       SUPRARRENALES                                     5\n\n\n\n     5.6 Carcinoma suprarrenal                                                                                                                 41  En relación con el tratamiento del carcinoma suprarrenal con mitotano, señale\n                                                                                                                                                   la respuesta falsa:\n              En relación con el tratamiento del carcinoma suprarrenal con mitotano, señale                                                        A. La resección quirúrgica completa es el único tratamiento potencialmente curativo para\n       40                                                                                                                                              el carcinoma corticosuprarrenal.\n              la respuesta falsa:                                                                                                                  B. Se sugiere el uso de mitotano adyuvante (sin quimioterapia) para pacientes con mayor\n              A. La zona glomerulosa es más resistente al efecto adrenolítico del mitotano.                                                            riesgo de recurrencia.\n              B. Se recomienda iniciar la terapia de reemplazo de glucocorticoides cuando se comienza                                              C. El uso de mitotano produce de forma rutinaria atrofia y/o inhibición esteroidogénica\n                  el tratamiento con mitotano.                                                                                                         de las glándulas suprarrenales normales, lo que provoca deficiencia de cortisol.\n              C. La mayoría de los pacientes tratados con mitotano requieren dosis sustitutivas                                                    D.  Tras la instauración del mitotano, el reemplazo de mineralocorticoides se debe de iniciar\n                  de glucocorticoides inferiores a las habituales.                                                                                     de inmediato.\n              D.  En los hombres que reciben terapia con mitotano, el hipogonadismo es común\n                  y, a menudo, requiere terapia de reemplazo de testosterona.                                                                      COMENTARIO\n              COMENTARIO                                                                                                                           El carcinoma suprarrenal primario es muy infrecuente, con una incidencia de 1:1.000.000\n                                                                                                                                                   de habitantes por año. El 80% de los tumores son funcionales, y lo más frecuente es que\n              El carcinoma suprarrenal primario es muy infrecuente, con una incidencia de 1:1.000.000                                              segreguen glucocorticoides solamente (45%), glucocorticoides y andrógenos (45%) o solo\n              de habitantes por        año. Las mujeres suelen verse afectadas                 con más      frecuencia que los                     andrógenos (10%).\n              hombres (2,5:1). La media de edad del comienzo es de 40 a 50 años, aunque los hombres                                                La cirugía ofrece la única opción de curación a los pacientes con enfermedad localizada.\n              tienden a una mayor edad en el momento del diagnóstico. El 80% de los tumores son fun-\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing literature reviews and clinical guidelines in various fields of medicine, including endocrinology.)\n##\n(\"entity\"<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>EVENT<|>A comprehensive medical textbook that covers various aspects of internal medicine, including adrenal disorders.)\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>ORGANIZATION<|>A professional organization that provides clinical practice guidelines for the management of endocrine disorders.)\n##\n(\"entity\"<|>MITOTANE<|>EVENT<|>Mitotane is a medication used in the treatment of adrenal carcinoma, often requiring careful management of glucocorticoid replacement therapy.)\n##\n(\"entity\"<|>CARCINOMA SUPRARENAL<|>EVENT<|>Adrenal carcinoma is a rare cancer with an incidence of 1 in 1,000,000 people per year, primarily affecting women and often requiring surgical intervention for localized disease.)\n##\n(\"entity\"<|>GLUCOCORTICOIDS<|>EVENT<|>Glucocorticoids are steroid hormones that are often involved in the treatment and management of adrenal disorders, including the need for replacement therapy in patients treated with mitotane.)\n##\n(\"relationship\"<|>UPTODATE INC.<|>HARRISON'S PRINCIPLES OF INTERNAL MEDICINE<|>UpToDate Inc. provides literature reviews that include references to Harrison's Principles of Internal Medicine<|>7)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF ENDOCRINOLOGY<|>UPTODATE INC.<|>The European Society of Endocrinology collaborates with UpToDate Inc. to provide clinical practice guidelines<|>6)\n##\n(\"relationship\"<|>MITOTANE<|>CARCINOMA SUPRARENAL<|>Mitotane is used as a treatment for adrenal carcinoma, indicating a direct relationship between the drug and the disease<|>8)\n##\n(\"relationship\"<|>CARCINOMA SUPRARENAL<|>GLUCOCORTICOIDS<|>Patients with adrenal carcinoma often require glucocorticoid replacement therapy, establishing a relationship between the disease and the treatment<|>7)\n##\n(\"relationship\"<|>MITOTANE<|>GLUCOCORTICOIDS<|>The use of mitotane in treatment often leads to the need for glucocorticoid replacement therapy, indicating a strong relationship<|>8)\n<|COMPLETE|>"}]}